Liminatus Pharma, Inc. — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Liminatus Pharma approved and executed a 1-for-50 reverse stock split of its common stock, effective August 20, 2026, reducing outstanding shares from ~67.2M to ~1.3M shares. The split was approved by stockholders on August 3, 2026, and trading on a split-adjusted basis began August 21, 2026 on Nasdaq under ticker LIMN with a new CUSIP (53271X207). Fractional shares were rounded up to the nearest whole share; proportionate ownership and voting power remain unchanged.
Why this rating
Reverse split is administrative capital structure change with no economic impact on shareholder ownership. Typically signals financial distress or Nasdaq compliance. Immaterial to $221M company.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.